Trial Profile
IcICLLe: Assessment of the Mechanism of Action of Ibrutinib (PCI-32765) in B-cell Receptor Pathway Inhibition in CLL
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 02 Jan 2024
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Obinutuzumab
- Indications Chronic lymphocytic leukaemia
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms IciCLLe
- 02 Jan 2024 Status changed from active, no longer recruiting to completed.
- 24 Apr 2023 Primary end point "Assessment of the proliferating cells" has been replaced by "Proportion of patients achieving MRD-negative remission", thus changing the trial focus from "PD" to "TU".
- 24 Apr 2023 Planned End Date changed from 1 Apr 2016 to 31 Dec 2023.